-
Machine Learning for Predictive Modeling of Hospitalization Risk in Myasthenia Gravis Patients Using the MGFA Global Patient Registry: Addressing Imbalanced Data in Real-World Evidence Scenarios
Mar 10, 2025, 14:00 PM -
Epidemiological Estimates of Interstitial Lung Diseases in Mexico: A Real-World Data Analysis of 2,591,278 Hospital Discharges From the Ministry of Health
Mar 10, 2025, 14:00 PM -
Real-World Treatment Patterns Among Patients With Scalp Psoriasis in Canada
Mar 10, 2025, 14:00 PM -
Defining Unmet Need to Optimize Management of Adults and Adolescents With Psoriasis: Development of a Global Multistakeholder Survey
Mar 10, 2025, 14:00 PM -
Household Costs and Other Societal Impacts for Individuals With Duchenne Muscular Dystrophy Stratified by Upper Limb Impairment: Results From a Caregiver Survey
Mar 10, 2025, 14:00 PM -
RtCGM Use is Associated with Improved Glycemic Control Compared to isCGM in Commercially Insured People with Type 2 Diabetes on Semaglutide and Insulin
Mar 10, 2025, 14:00 PM -
Association of Sleep Disturbances With Mild Cognitive Impairment Among Adults in the US
Mar 10, 2025, 14:00 PM -
Examination of Factors Influencing Colorectal Screening Participation
Mar 10, 2025, 14:00 PM -
Differential Item Functioning With the National Eye Institute Visual Function Questionnaire-25 in Patients With Vitreomacular Traction
Mar 10, 2025, 14:00 PM -
Estimating Quality-Adjusted Life Years and Life-Years Gained in Glioblastoma Patients: Analysis from the TIGER Trial
Mar 10, 2025, 14:00 PM -
Provider perspectives on the DREAMM-7 Trial Results and Belantamab Mafodotin (belamaf) in Combination with Bortezomib and Dexamethasone (B-Vd) as a Potential Treatment for Patients with Relapsed or Refractory Multiple Myeloma (R/R MM)
Mar 10, 2025, 14:00 PM -
Concomitant Usage of Contra-Indicated Medications in Patients With Atrial Fibrillation: A Comparison of Real-World Data Sources in the United States
Mar 10, 2025, 14:00 PM -
Estimating the Potential Cost-Effectiveness of Long-Acting Naltrexone versus Oral Naltrexone for Alcohol Use Disorder
Mar 10, 2025, 14:00 PM -
Evaluating the Impact of Luxturna Gene Therapy on Vision Improvement and Disease Progression in Patients With RPE65 Mutation-Associated Inherited Vision Loss
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness Analysis of Olaparib and Niraparib With Abiraterone Versus Abiraterone for First-Line Treatment of BRCA Mutated Metastatic Castration-Resistant Prostate Cancer in Taiwan
Mar 10, 2025, 14:00 PM -
Assessing the Added Value of Fixed-Dose Combinations in Non-Communicable Diseases: A Comparative HTA Analysis Across Canada, Scotland, France, and Germany (2014-2024)
Mar 10, 2025, 14:00 PM -
Optimizing Adherence to Intravenous Iron: A Geographic Analysis of Variability Within the United States
Mar 10, 2025, 14:00 PM -
Prescribing Trends of Disease-Modifying Medications in Texas Medicaid Enrollees with Sickle Cell Disease
Mar 10, 2025, 14:00 PM -
Staffing Resource Use: A Cost Impact Model for the Utilization and Implementation of Medications for Opioid Use Disorder Within US Jails And Prisons
Mar 10, 2025, 14:00 PM -
Uncovering the Cost of Red Blood Cell (RBC) and Platelet (PLT) Transfusions in Africa, Asia, Oceania, and the Americas and Exploring Related Implications in a Trial Example
Mar 10, 2025, 14:00 PM
